BAY 2927088 is an oral medication being studied for its effectiveness and safety in treating certain types of advanced solid tumors. It works by inhibiting specific proteins known as tyrosine kinases, which are involved in the growth and spread of cancer cells. This medication is being tested in patients whose tumors have specific mutations that activate a protein called HER2, which can promote cancer progression. The goal of the study is to see how well this medication can reduce the size of tumors or stop them from growing.

Advanced Solid Tumors – These are a group of cancers that originate in solid organs or tissues, such as the breast, lung, or colon, and have progressed to an advanced stage. At this stage, the tumors have typically spread beyond their original location to other parts of the body. The progression of these tumors can vary depending on the type and location of the cancer, as well as individual patient factors. They often grow and spread more aggressively, making them more challenging to manage. The symptoms and impact on the body can be significant, affecting various bodily functions and overall health.

HER2 Mutation – This refers to a genetic alteration in the human epidermal growth factor receptor 2 (HER2) gene, which can lead to the overproduction of the HER2 protein. This protein is involved in cell growth and division, and its overexpression can cause cells to grow uncontrollably, contributing to the development of certain types of cancer, such as breast and gastric cancers. The mutation can result in more aggressive tumor behavior and influence the progression of the disease. It is a significant factor in determining the characteristics and potential treatment approaches for the cancer. The presence of a HER2 mutation can affect the growth rate and spread of the cancer cells.